GLYBERA Canadian Trademark Information

On Tuesday, October 7, 2014, a canadian trademark registration was filed for GLYBERA by uniQure IP B.V. *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1697071. The current status of this trademark filing is Interruption of proceeding. The correspondent listed for GLYBERA is LAVERY, DE BILLY, LLP of *********, **********, ***** **** The GLYBERA trademark is filed in the description of Biological preparations for use in medical and clinical gene therapy and cell therapy; clinical medical reagents for use in gene therapy, gene diagnosis, and gene testing; pharmaceutical preparations, namely vaccines for use in gene therapy; all the aforementioned wares exclusively in the treatment of metabolic disorders; gene therapy and prophylaxis products, namely gene-based biological preparations and medical reagents for use in gene delivery, gene transfer, gene regulation and gene modulation for the treatement of metabolic disorders; gene therapy and prophylaxis products, namely gene-based biological preparations and medical reagents for use in gene delivery, gene transfer, gene regulation and gene modulation for the treatment of metabolic disorders, ocular disorders, central nervous system diseases, brain diseases, brain stem diseases, spinal cord diseases, peripheral nervous system diseases, autonomous nervous system diseases, sensory organ diseases, infectious nervous system diseases, degenerative nervous system diseases, inherited nervous system diseases, vascular nervous system diseases, immune nervous system diseases, post-trauma nervous system diseases, acute spinal cord injury, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Bell's palsy, brain aneurysm, brain tumors, epilepsy, seizures, Guillain-Barré syndrome, head injury, headache, lumbar disc disease (herniated disc), meningitis, multiple sclerosis, muscular dystrophy, normal pressure hydrocephalus, Parkinson's disease, stroke (brain attack), blood disorders, cancer, inflammation and inflammatory disorders, auto-immune diseases, vascular disorders, and single gene disorders; all the aforesaid as relating to metabolic disorders .